shRNA apolipoprotein B100 gene siliencer (AMT)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameshRNA apolipoprotein B100 gene siliencer (AMT)
Drug Alias NameAAV-shApoBapoB100 shRNA AAV-based gene therapy (Amsterdam Molecular Therapeutics)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionApolipoprotein B-100 inhibitors
TargetsApolipoprotein B-100
Therapy Area/IndicationsHypercholesterolemiaCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmsterdam Molecular Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmsterdam Molecular Therapeutics
Active IndicationsN/A
Inactive IndicationsHypercholesterolemiaCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A